TRINETRA › Sectors › Healthcare
Fortis Healthcare Limited (FORTIS) — share price, P/E and fundamentals
Fortis Healthcare Limited (NSE: FORTIS) closed at ₹768.15 on 30 Oct 2026, -29.2% over one year, against a 52-week range of ₹704.95 – ₹1,104.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 6 Aug 2026) it reported revenue of ₹2,545 cr and net profit of ₹266 cr, a 10.5% net margin; revenue grew 17.5% and profit grew 3.2% year on year.
On four consecutive filed quarters its trailing P/E is 55.3; since 20 May 2025 its own P/E has ranged from 51.2 to 107.0 (median 74.5), and today's reading is higher than 4% of those 358 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 10.8%, ROCE 12.7%, debt-to-equity 0.29, Piotroski F-score 8 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 25% of 63 sector peers; PBT margin higher than 27% of 63 sector peers; ROE higher than 29% of 63 sector peers.
Key figures
| Last close | ₹768.15 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -12.4% / -17.3% / -29.2% |
| 52-week low – high | ₹704.95 – ₹1,104.00 |
| Market capitalisation | ₹57,992 cr |
| Trailing P/E | 55.3 |
| Price / book | 5.86 |
| EV / EBITDA | 28.0 |
| Earnings yield | 1.8% |
| TTM EPS | ₹13.88 |
| TTM net profit | ₹1,048 cr |
| Quarter revenue | ₹2,545 cr |
| Quarter net profit | ₹266 cr |
| Net margin | 10.5% |
| Revenue growth (YoY) | +17.5% |
| Profit growth (YoY) | +3.2% |
| Return on equity | 10.8% |
| ROCE | 12.7% |
| Debt / equity | 0.29 |
| Current ratio | 0.86 |
| Free cash flow | ₹656 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹97.8 cr |
Against Healthcare peers
| Metric | FORTIS | Peer median | Percentile |
|---|---|---|---|
| Net margin | 10.47 | 12.89 | 25 |
| PBT margin | 14.10 | 17.68 | 27 |
| ROE | 10.77 | 13.87 | 29 |
| ROCE | 12.69 | 17.26 | 22 |
| Debt / equity | 0.29 | 0.11 | 70 |
| Cash conversion | 1.51 | 1.25 | 72 |
| Trailing P/E | 55.34 | 43.07 | 64 |
| P/B | 5.86 | 6.02 | 48 |
Questions
What is the P/E ratio of Fortis Healthcare Limited?
Fortis Healthcare Limited's trailing P/E is 55.3, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 20 May 2025 its P/E has ranged 51.2–107.0.
What were Fortis Healthcare Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Fortis Healthcare Limited reported revenue of ₹2,545 cr and net profit of ₹266 cr (consolidated), filed with the exchange on 6 Aug 2026.
What is Fortis Healthcare Limited's ROE?
Return on equity is 10.8% based on the balance sheet dated 31 Mar 2026.
Does Fortis Healthcare Limited have debt?
Debt-to-equity is 0.29 on the balance sheet dated 31 Mar 2026.
What is FORTIS's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, FORTIS traded between ₹704.95 and ₹1,104.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.